2016 Fiscal Year Final Research Report
Basic studies on P2Y12 receptor antagonists as candidates for antimetastatic agents
| Project/Area Number |
26460244
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Mukogawa Women's University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | P2Y12受容体拮抗薬 / クロピドグレル / チクロピジン / がん転移 / がん細胞浸潤能 / がん細胞遊走能 / Vimentin / MMP-2 |
|---|
| Outline of Final Research Achievements |
First, we demonstrated that orally administered Clopidogrel, a P2Y12 receptor antagonist, inhibited lung metastasis in mice intravenously injected with B16-BL6 mouse melanoma cells.
To elucidate the mechanism of antimetastatic action of P2Y12 receptor antagonists, the effects of Clopidogrel and Ticlopidine on cell motility and invasiveness were measured by chemotaxis assay and chemoinvasion assay, respectively. Clopidogrel significantly reduced both cell motility and invasiveness in a dose-dependent manner. Ticlopidine also significantly reduced cell motility in a dose-dependent manner. Furthermore, Clopidogrel reduced the protein expression level of Vimentin, while Ticlopidine significantly reduced Matrix metalloproteinase-9 (MMP-9) activity and the protein expression level of MMP-2.
|
| Free Research Field |
腫瘍薬理学
|
